Inhibition of Endotoxin-Induced Uveitis by Methylprednisolone Acetate Nanosuspension in rabbits

Adibkia, K. and Omidi, Y. and Javadzadeh, A.R. and Barzegar-Jalali, M. and Barar, J. and Maleki, N. and Mohammadi, G. and Nokhodchi, A. (2007) Inhibition of Endotoxin-Induced Uveitis by Methylprednisolone Acetate Nanosuspension in rabbits. Journal of Ocular Pharmacology and Therapeutics, 23 (5). pp. 421-432. ISSN 1080-7683. (The full text of this publication is not available from this repository)

The full text of this publication is not available from this repository. (Contact us about this Publication)
Official URL
http://dx.doi.org/10.1089/jop.2007.0039

Abstract

Purpose: In the current investigation, nanoformulations of methylprednisolone acetate(MPA) were formulated using Eudragit®RS100 to study their impacts on inhibition of inflammatory symptoms in rabbits with endotoxin-induced uveitis (EIU).Methods: A modified quasi-emulsion solvent diffusion (QESD) technique was used for preparation of nanoparticles. The drug release profiles and physicochemical characteristics of the nanoformulations were studied by means of the X-ray crystallography, differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FT-IR). Particle size analysis yielded mean diameter of approximately 380, 460 and 580 (nm) for MPA-Eudragit®RS100 nanoparticles at the ratios of 1:2.5, 1:5 and 1:10, respectively. Major clinical symptoms of EIU (morphological changes, leukocytes numbers and protein levels within the aqueous humor) were examined. Results: Upon the physicochemical characterizations, no crystal changes or chemical interactions were observed for MPA-Eudragit®RS100 nanoparticles. The 1:2.5 ratio of drug-polymer resulted in the most controlled release of MPA. The in vivo examinations revealed that the endotoxin induced inflammation can be inhibited by the MPA-Eudragit® RS100 nanosuspension more significantly than the microsuspension of MPA itself in the rabbits with EIU. Conclusion: Based on our findings, we suggest that the MPA-Eudragit®RS100 nanosuspension may favor the localized controlled ocular delivery of MPA for prevention of inflammatory symptoms in ocular diseases.

Item Type: Article
Subjects: Q Science
Divisions: Faculties > Science Technology and Medical Studies > Medway School of Pharmacy
Depositing User: Ali Nokhodchi
Date Deposited: 10 Jul 2008 12:44
Last Modified: 08 May 2012 11:22
Resource URI: http://kar.kent.ac.uk/id/eprint/10060 (The current URI for this page, for reference purposes)
  • Depositors only (login required):